Kuelbs Family Office Invests In Biotech Company Elevian, Supporting
11/05/21, 12:00 AM
Location
dallas“We are pleased to have the Kuelbs family as investors in Elevian and John as a business advisor,” said Dr. Mark Allen, Co-Founder and CEO of Elevian. “His insight and experience building valuable companies across numerous industries provide a valuable perspective to the company.”
Company Info
Location
dallas, georgia, united states
Additional Info
Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases. Elevian's scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that treatment with the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues. Elevian has acquired exclusive, worldwide rights to Harvard's patent portfolio concerning GDF11. The company is developing new medicines that target the GDF11 pathway. Elevian's lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models of stroke, obesity, Type 2 diabetes, heart failure, Alzheimer's disease, and many other age-related diseases. The company has also established additional programs focused on the discovery and development of novel proteins, antibodies and small molecule drugs that target the GDF11 pathway. For more information, please visit http://www.elevian.com